Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shingrix Gets China Nod But Won’t Launch Until 2020 Amid Strong Demand

Executive Summary

Following a priority review, Shingrix may become the next hit vaccine in China as millions seek preventative care, but GSK is being cautious over supply plans.

You may also be interested in...



Ready To Ride Next Growth Wave In China? Remember Five Keys

As China enters a new growth spur for the health sector, underscored by faster product approvals, annual reimbursement coverage and strong demand for high-quality treatments, strategic planning and meticulous execution are more important than ever if companies want to win in the world's second-largest pharma market, says a new report.

No Room For Error: China Proposes Hefty Fines On Quality Violations In Drug Law Overhaul

A proposed revision to China's Drug Administration Law will crack down on GMP violations with hefty fines, while a dedicated law proposes additional scrutiny over imported vaccines.

China Appetite For HPV Vaccine Delivers Surprise For Merck

When Merck realized that demand in China is so large for its HPV vaccine Gardasil, the US company wanted to understand more about the market, but a coordinated pre-launch awareness campaign appears to have helped. 

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS125352

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel